Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant
Abstract
No abstract availableKeywords
Funding Information
- Morris Animal Foundation (DC13-501A)
- University of Iowa, College of Public Health
- Department of Epidemiology
- Bill and Melinda Gates Foundation (631, 39129)
- National Institutes of Health (AI25038)
- Carver College of Medicine
- Holden Comprehensive Cancer Center
- Iowa City Veteran’s Administration Medical Center
This publication has 63 references indexed in Scilit:
- Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in DogsPLOS Neglected Tropical Diseases, 2015
- From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH‐F3+GLA‐SEClinical & Translational Immunology, 2015
- Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantumVaccine, 2015
- Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?Expert Review of Anti-infective Therapy, 2014
- Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral LeishmaniasisPLOS Neglected Tropical Diseases, 2013
- Leishmaniasis: complexity at the host–pathogen interfaceNature Reviews Microbiology, 2011
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine AdjuvantPLOS ONE, 2011
- Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infectionVaccine, 2009
- Vaccines for leishmaniasis in the fore coming 25 yearsVaccine, 2008
- Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f®+MPL-SE® vaccine to treat canine visceral leishmaniasisVaccine, 2008